デフォルト表紙
市場調査レポート
商品コード
1698161

細胞療法市場-世界の産業規模、シェア、動向、機会、予測、治療タイプ別、治療領域別、地域別、競合別、2020-2030年

Cell Therapy Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Therapy Type, By Therapeutic Area, By Region & Competition, 2020-2030F

出版日
ページ情報
英文 185 Pages
納期
2～3営業日
カスタマイズ可能
細胞療法市場-世界の産業規模、シェア、動向、機会、予測、治療タイプ別、治療領域別、地域別、競合別、2020-2030年
出版日: 2025年03月28日
発行: TechSci Research
ページ情報: 英文 185 Pages
納期: 2～3営業日
GIIご利用のメリット

  • 全表示

  • 概要
  • 目次
概要

細胞療法の世界市場規模は2024年に63億米ドルとなり、2030年までのCAGRは12.01%で、予測期間中に大きな成長が見込まれます。

現代医学の領域では、科学とイノベーションの融合により、かつてはSFの世界と考えられていたような画期的な治療法が誕生しています。そのような画期的な進歩の一つが細胞療法であり、生きた細胞の力を利用して様々な病気や症状を治療する最先端の医療アプローチです。世界の細胞療法市場は急速に拡大しており、患者に新たな希望をもたらし、ヘルスケア提供のあり方にパラダイムシフトを生み出しています。細胞療法は、損傷した組織や病気の組織の修復、再生、置換を刺激するために、患者の体内に生きた細胞を移植したり操作したりすることを含みます。これらの細胞は、患者自身の体から（自家）またはドナーから（同種）供給されます。細胞療法の治療的可能性は、対症療法に重点を置くことが多い従来の治療とは異なり、様々な疾患の根本原因を細胞レベルでターゲットにする能力にあります。細胞療法の世界市場は、その有望な成果と細胞生物学への理解の高まりにより、近年大きな勢いを見せています。

市場概要
予測期間 2026-2030
市場規模：2024年 63億米ドル
市場規模：2030年 124億7,000万米ドル
CAGR：2025年～2030年 12.01%
急成長セグメント オンコロジー
最大市場 北米

市場促進要因

慢性疾患と変性疾患の有病率の増加

主な市場課題

複雑な規制状況

主要市場動向

技術の進歩

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 細胞療法市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • 治療の種類別（自家移植、同種移植）
    • 治療領域別（腫瘍学、心血管疾患、筋骨格系疾患、皮膚科）
    • 地域別
    • 企業別（2024）
  • 市場マップ

第6章 北米の細胞療法市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 北米：国別分析
    • 米国
    • カナダ
    • メキシコ

第7章 欧州の細胞療法市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 欧州：国別分析
    • ドイツ
    • 英国
    • イタリア
    • フランス
    • スペイン

第8章 アジア太平洋地域の細胞療法市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • アジア太平洋地域：国別分析
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア

第9章 南米の細胞療法市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 南米：国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第10章 中東・アフリカの細胞療法市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 中東・アフリカ：国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦

第11章 市場力学

  • 促進要因
  • 課題

第12章 市場動向と発展

  • 最近の動向
  • 製品上市
  • 合併と買収

第13章 世界の細胞療法市場：SWOT分析

第14章 競合情勢

  • Novartis AG
  • Gilead Sciences, Inc.
  • Bristol-Myers Squibb Company
  • Johnson & Johnson Services, Inc
  • JCR Pharmaceuticals Co., Ltd.
  • Tego Science
  • Atara Biotherapeutics
  • Takeda Pharmaceutical Company Limited
  • Bluebird Bio, Inc.
  • Dendreon Corp..

第15章 戦略的提言

第16章 調査会社について・免責事項

目次
Product Code: 17182

Global Cell Therapy Market was valued at USD 6.30 Billion in 2024 and is anticipated to project formidable growth in the forecast period with a CAGR of 12.01% through 2030. In the realm of modern medicine, the convergence of science and innovation has given rise to transformative treatments that were once considered science fiction. One such groundbreaking advancement is cell therapy, a cutting-edge medical approach that harnesses the power of living cells to treat a range of diseases and conditions. The global cell therapy market is rapidly expanding, offering new hope for patients and creating a paradigm shift in the way healthcare is delivered. Cell therapy involves the transplantation or manipulation of living cells into a patient's body to stimulate the repair, regeneration, or replacement of damaged or diseased tissues. These cells can be sourced from the patient's own body (autologous) or from a donor (allogeneic). The therapeutic potential of cell therapy lies in its ability to target the root causes of various diseases at a cellular level, unlike traditional treatments that often focus on symptom management. The global cell therapy market has gained substantial momentum in recent years due to its promising outcomes and a growing understanding of cellular biology.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 6.30 Billion
Market Size 2030USD 12.47 Billion
CAGR 2025-203012.01%
Fastest Growing SegmentOncology
Largest MarketNorth America

Key Market Drivers

Increasing Prevalence of Chronic and Degenerative Diseases

The rising prevalence of chronic and degenerative diseases is one of the primary factors fueling the expansion of the Global Cell Therapy Market. In 2020, an estimated 523 million individuals globally were affected by cardiovascular diseases (CVDs), with approximately 19 million fatalities attributed to these conditions. This accounted for nearly 32% of all global deaths and reflected an 18.7% increase in absolute mortality compared to 2010. As conventional treatment methods often fail to provide long-term solutions for these conditions, cell therapy is emerging as a breakthrough alternative, offering regenerative and disease-modifying potential. In 2021, noncommunicable diseases (NCDs) were responsible for at least 43 million deaths worldwide, accounting for 75% of all non-pandemic-related fatalities. Alarmingly, 18 million of these deaths occurred in individuals under the age of 70, with 82% of premature fatalities concentrated in low- and middle-income countries. This growing burden highlights a significant unmet medical need for more effective, accessible, and preventive healthcare solutions, particularly in regions with limited resources. Chronic and degenerative diseases such as cancer, cardiovascular diseases, autoimmune disorders, diabetes, and neurodegenerative conditions pose a significant global healthcare burden. Traditional treatment options, including pharmaceuticals and surgical interventions, often provide only symptom relief rather than disease reversal or regeneration. Cell therapy, particularly stem cell and immune cell-based treatments, offers a transformative approach by promoting tissue regeneration, reducing inflammation, and potentially curing previously untreatable diseases. As the global population ages and chronic disease prevalence rises, demand for more effective, long-term solutions is accelerating investment and adoption of cell therapies.

Key Market Challenges

Complex Regulatory Landscape

One of the foremost challenges in the cell therapy market is navigating the complex and evolving regulatory landscape. Unlike traditional pharmaceuticals, which are based on small molecules, cell therapies involve live cells that interact with the patient's body. This dynamic nature raises unique safety and efficacy concerns, leading to intricate regulatory requirements. Ensuring compliance with these regulations can be time-consuming and resource-intensive, potentially delaying the development and approval process.

Key Market Trends

Technological Advancements

The field of medical science is undergoing a transformative phase, with remarkable breakthroughs occurring at an unprecedented pace. Among these groundbreaking advancements, cell therapy stands out as a beacon of hope, promising revolutionary treatments for a multitude of diseases that were once considered untreatable. As technological innovations continue to accelerate, the cell therapy market is experiencing a rapid expansion, offering new avenues for treating a diverse range of medical conditions. Stem cells, with their unique ability to differentiate into various cell types, have captured the attention of researchers and clinicians alike. Advances in stem cell isolation, manipulation, and differentiation techniques have enabled the development of personalized therapies for conditions ranging from neurodegenerative disorders to cardiovascular diseases. The emergence of precise gene editing tools like CRISPR-Cas9 has revolutionized the field of cell therapy. This technology allows scientists to modify a cell's genetic material, correcting mutations or enhancing desired traits before transplantation. Gene-edited cells offer improved therapeutic potential and reduced risks of immune rejection. Immunotherapies harness the body's immune system to target and destroy disease-causing cells. Chimeric Antigen Receptor (CAR) T-cell therapy, a form of immunotherapy, has shown remarkable success in treating certain types of leukemia and lymphoma. Ongoing research aims to expand the applications of CAR-T therapy to solid tumors and other diseases. Microfluidic devices and automated systems have streamlined the production and manipulation of cells for therapy. These technologies enhance scalability, consistency, and quality control, ensuring that cell-based treatments can be manufactured in large quantities without compromising safety and efficacy. As technology continues to evolve, the cell therapy market is projected to experience exponential growth. The convergence of these technological advancements has propelled the development of novel and effective therapies for conditions that were once considered incurable. From autoimmune diseases to degenerative disorders, the spectrum of diseases that can potentially be addressed through cell therapy continues to expand. However, it's important to note that along with the potential benefits, challenges remain. Safety concerns, regulatory hurdles, and the complexities of manufacturing consistent and viable cell therapies on a large scale are among the issues that need to be addressed to fully realize the potential of this field.

Key Market Players

  • Novartis AG
  • Gilead Sciences, Inc.
  • Bristol-Myers Squibb Company
  • Johnson & Johnson Services, Inc
  • JCR Pharmaceuticals Co., Ltd.
  • Tego Science
  • Atara Biotherapeutics
  • Takeda Pharmaceutical Company Limited
  • Bluebird Bio, Inc.
  • Dendreon Corp.

Report Scope:

In this report, the Global Cell Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cell Therapy Market, By Therapy Type:

  • Autologous
  • Allogenic

Cell Therapy Market, By Therapeutics Area:

  • Oncology
  • Cardiovascular Diseases
  • Musculoskeletal Disorders
  • Dermatology

Cell Therapy Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cell Therapy Market.

Available Customizations:

Global Cell Therapy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Cell Therapy Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Therapy Type (Autologous, Allogenic)
    • 5.2.2. By Therapeutic Area (Oncology, Cardiovascular Diseases, Musculoskeletal Disorders, Dermatology)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Cell Therapy Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Therapy Type
    • 6.2.2. By Therapeutics Area
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Cell Therapy Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Therapy Type
        • 6.3.1.2.2. By Therapeutics Area
    • 6.3.2. Canada Cell Therapy Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Therapy Type
        • 6.3.2.2.2. By Therapeutics Area
    • 6.3.3. Mexico Cell Therapy Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Therapy Type
        • 6.3.3.2.2. By Therapeutics Area

7. Europe Cell Therapy Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Therapy Type
    • 7.2.2. By Therapeutics Area
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Cell Therapy Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Therapy Type
        • 7.3.1.2.2. By Therapeutics Area
    • 7.3.2. United Kingdom Cell Therapy Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Therapy Type
        • 7.3.2.2.2. By Therapeutics Area
    • 7.3.3. Italy Cell Therapy Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Therapy Type
        • 7.3.3.2.2. By Therapeutics Area
    • 7.3.4. France Cell Therapy Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Therapy Type
        • 7.3.4.2.2. By Therapeutics Area
    • 7.3.5. Spain Cell Therapy Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Therapy Type
        • 7.3.5.2.2. By Therapeutics Area

8. Asia-Pacific Cell Therapy Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Therapy Type
    • 8.2.2. By Therapeutics Area
    • 8.2.3. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Cell Therapy Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Therapy Type
        • 8.3.1.2.2. By Therapeutics Area
    • 8.3.2. India Cell Therapy Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Therapy Type
        • 8.3.2.2.2. By Therapeutics Area
    • 8.3.3. Japan Cell Therapy Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Therapy Type
        • 8.3.3.2.2. By Therapeutics Area
    • 8.3.4. South Korea Cell Therapy Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Therapy Type
        • 8.3.4.2.2. By Therapeutics Area
    • 8.3.5. Australia Cell Therapy Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Therapy Type
        • 8.3.5.2.2. By Therapeutics Area

9. South America Cell Therapy Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Therapy Type
    • 9.2.2. By Therapeutics Area
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Cell Therapy Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Therapy Type
        • 9.3.1.2.2. By Therapeutics Area
    • 9.3.2. Argentina Cell Therapy Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Therapy Type
        • 9.3.2.2.2. By Therapeutics Area
    • 9.3.3. Colombia Cell Therapy Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Therapy Type
        • 9.3.3.2.2. By Therapeutics Area

10. Middle East and Africa Cell Therapy Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Therapy Type
    • 10.2.2. By Therapeutics Area
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Cell Therapy Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Therapy Type
        • 10.3.1.2.2. By Therapeutics Area
    • 10.3.2. Saudi Arabia Cell Therapy Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Therapy Type
        • 10.3.2.2.2. By Therapeutics Area
    • 10.3.3. UAE Cell Therapy Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Therapy Type
        • 10.3.3.2.2. By Therapeutics Area

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Cell Therapy Market: SWOT Analysis

14. Competitive Landscape

  • 14.1. Novartis AG
    • 14.1.1. Business Overview
    • 14.1.2. Product & Service Offerings
    • 14.1.3. Recent Developments
    • 14.1.4. Financials (If Listed)
    • 14.1.5. Key Personnel
    • 14.1.6. SWOT Analysis
  • 14.2. Gilead Sciences, Inc.
  • 14.3. Bristol-Myers Squibb Company
  • 14.4. Johnson & Johnson Services, Inc
  • 14.5. JCR Pharmaceuticals Co., Ltd.
  • 14.6. Tego Science
  • 14.7. Atara Biotherapeutics
  • 14.8. Takeda Pharmaceutical Company Limited
  • 14.9. Bluebird Bio, Inc.
  • 14.10.Dendreon Corp..

15. Strategic Recommendations

16. About Us & Disclaimer